Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03842969 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 236
- Enrollment target
NCT03842969 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 236 participants.
The verdict
NCT03842969, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 236 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.
Interventions
- DRUG RO7234292 (RG6042)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03842969
The ClinicalTrials.gov registry entry for NCT03842969 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO7234292 (RG6042) is the first listed.
NCT03842969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03842969 about?
NCT03842969 is a clinical study titled "An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies". This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.
What is the current status of trial NCT03842969?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 236 participants. The study started on 2019-04-23. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT03842969?
The interventions under investigation include: RO7234292 (RG6042) (DRUG).
Who is sponsoring clinical trial NCT03842969?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.